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FOREWORD:
ACADEMIC-INDUSTRY COLLABORATIONS IN THE CLINIC
The "genetics revolution" has reached the clinic.1 Consequentially, clinical
research has been infused with unprecedented innovation and potential for
improving human health. 2 However, the maturation of contemporary biomedical
research

also has advanced an

complications

associated

with

entanglement
intense

of

ethical and regulatory

academic-industry

collaboration,

competition, and commercialization.3 Critics and many concerned participants
claim that the life science communities and policy makers have launched this
genetic revolution in science, and brought research into an era of academic
industry alliances, without first establishing sufficient safeguards to ensure the
protection of human subjects and the integrity of research. 4�In response to this
concern and related controversies which have captured media attention,5 the

1. For identification of the drug development pipeline, see http:/ /www.phrma.org (last
visited Aug. 23, 2001) (site of the Pharmaceutical Researchers and Manufacturers of America

(PhRMA), the world's leading phannaceutical trade organization); http:/ /www.bio.org (last visited

Aug. 23,

2001) (site of the Biotechnology Industry Organization (BIO), the world's leading

biotechnology i ndustry trade organization); http:/ /www.clinicaltrials.gov (last visited Aug. 23, 2001)

(details on approximately

5,SOO mostly government-funded clinical trials); http://cancertrials.

nci.n ih.gov (last visited Aug. 23, 2001) (the National Cancer lnstitute's clinical trial li.�ting);
http:/ /www .actis.org (last visited Aug. 23, 2001) (the AIDS clinical trial information service
(ACTIS)); http:/ /www.centeiwatch.com (last visited Aug. 23, 2001) (one of the earliest and the

most comprehensive private sites); http://www.emergingrned.com (last visited Aug. 23, 2001)
(privately-funded cancer trials; under e xp a nsio n to cover other

diseases); http:// www.

veritasrnedicine.com Oast visited Aug. 23, 2001) (list� trials and standard treatments for numerous
diseases); http://www .americasdoctor.com (last visited Aug. 23, 2001) (trials in various disease
categories, excluding cancer); and http:/ /www.acurian.com Qast visited Aug. 23, 2001) (developing

lists of trials in numerous disease categories).
2. Stt generai!J JlljJra note 1.

3. Stt Press Release, Department of Health and Human Services, Secretary Shalala Bolsters
Protections for Human Research Subjects (May 23, 2000) [hereinafter DHHS Press Release],
avai/ab/e athttp://www .hhs.gov/news/press/2000pres/20000523.htrnl. Seea/soElizabethA.Boyd
& Lisa A. Bero, Am;.sing F1Jt11/Jy Financial &latiomhips With Indmtry: A

Cast St11tfy, 284 JAMA 2209

(2000); Mildred K. Cho et al., Po/icie; on Faat/!y Conjlim oflnttml at US Uniwr.sititJ, 284 JAMA 2203
(2000); Catherine D. DeAngelis, Conflid oflntemt and the P11b/i, Tf'llJI, 284 JAMA 2237 (2000). See

gentral!J David Korn, Conjli&/; ofIntm;t in Bio1111di&al RJJtar,rh 284 JAMA 2234 (2000) .
4. See, 1.g., DHHS Press Release, JlljJranote 3 (addressing the need to bolster protections for
ENG. J.
human subjects); Donna Shalala, Prottding &semrh S11Uj1as-What M11st Bt Drm, 343 NEW
,
MED. 808 (2000).
S. The incident which has captured the most attention is the circumstances surrounding
the death of Jesse Gelsinger, an 18-year-old gene-therapy subject in a protocol approved by the
University of Pe n nsylvan ia. Stt Gelsinger v. Trustees of the Univ. of Pa., Case No. 000901885 (Ct.
Corn. Pl., Phila. County, filed Sept. 18, 2000), athttp://www.ssluplaw.com/ l.inks/healthcare2.html
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United States (including the government, industry, and academia sectors), is
reassessing the soundness of its regulatory regimes to protect human subjects and
research integrity.6 Consequentially, fundamental reform is being contemplated

in t he midst of an extraordinary amount of important, ongoing clinical research.7
On March 15, 2001, approximately 200 representatives from the biomedical
industry, the medical conununity, gov ernment agencies, and multiple disciplines
in academia gathered at the Widener University School of Law's Delaware
campus to advance critical thinking about this pressing topic. This effort was a
shared undertaking by the Widener Lzw SympoJium Journaland the Widener Health

Law Institute in cooperation with the American Bar Association, Delaware Bar
A ssociation,

Pennsylvania

Bar

Association,

Pennsylvania

Biotechnology

A ssociation, and with the financial sponsorship of Centocor, Inc. and Eckert
Seamans Cherin & Mellott, LLC.
The primary objective of the conference was to bridge legal academia with the
life science and medical communities and to create a forum that could make a
meaningful "real world" contribution through pragmatic discussion and by
raising awareness. This issue of the Widener Law Sympoti11111 ]o111'1a
1 l contains a
collection of written contributions originating from and complementing the livdy
and informative conference proceedings.

Oast visited Aug. 23, 2001); Thomas Petzinger Jr.,

Yes, Ttch11oloo S1t1111 to Cho11ge Almost Dai!J. B11t

Some Tmulr are Lllu!y Jo Remain in Forcefar 11 Ltmg Time, WAIL ST. J., Jan. 1, 2000, at R12.
6. The Department of Health & Human Services (D HHS), Office of the Secretary, hosted
a forum on August 15-16, 2000, entitled "Human Subject Protection and Financial Conflict of
Interest." This forum also was sponsored by the National Institutes of Health (NIH), Centers for
Disease Control (CDC), and Food & Drug Administration (FDA). Sn Agenda. Human Subject
Protection and Financial Conflicts of Interest Conference
ohrp.osophs.dhhs.govI coifa genda. httn.

(Aug.

15,

2000), at http:/I

Subsequently, NIH undertook "visits" to recipient

institutions throughout the country to see first-hand how they a.re dealing with conflicts of interest.

See Patrick Healy, Ht1n1ard For11111 Eye.r Ovmight ofBiometliMI&.r1arrh, BoSTON GLOBE , July 21, 2000,
at A13. More signjficantly, the FDA issued guidance to assist industry in dealing with potential
conflicts of interests. FOOD & DRUG ADMJN., DEPT HEALrn & HUMAN SERVS., GUIDANCE FOR
INDUSTRY:

FINANCfAL

DISCLOSURE

BY

C L I N ICA L

INVESTIGATOR S

(2001),

11/

http:/I www.fda.gov/ oc/ guidance/ financialdis.html (last visited Sept. 4, 2001). Along these same
lines, representatives from several of the nation's top medical schools (Harvard, Baylor College of
Medicine, Columbia University, Johns Hopkins University, the University of Pennsylvania, the
Uni versity of Washington, Washington University, Yale University, and the University of California
at San Francisco and Los Angeles) have jointly drafted proposed conflict of interest guidelines that
require researchers to disclose any financial interests they have in studies involving patients. Ste
Carey Goldberg, Medical School!

Offer Ralls 011 Doctors' Co11flid ofI11tm.1t, N.Y. TIMES, Feb. 8, 2001, at

A23. Several Professional Societies, including the American Society of Human Genetics, have done

the same. stt AME R. Soc'y OF GENE T HERAPY (A SG1) , POLICY OF THE AMERICAN SOCIETY OF

GENE THERAPY ON FINANCIAL CONFLICT OF INTEREST IN CLINICAL REsEARCH
http://www.asgt.org/policy/index.html (last visited Sept. 4, 2001).
7. See general!J supra note 1.
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(2000), at

The issue begins with two overview pieces. First, in Financial Conflicts ofInterest:

How are we Managing?,8 Erica Rose surveys a multitude of fundamental issues
introduced by financial conflicts of interest, including how conflicts of interest
arise and attempts to identify and manage them.

Second, in Globalization of

Interests and Clinical R.esearch: An Overview of Trends and Issues,9 Timothy Caulfield
surveys the trends of globalization and commercialization in clinical research

relating to the issue of conflicts of interest. Caulfield sets forth several proposals,
including the need to create research policy and Institutional Review Board
structures to minimize conflicts and reduce the threat of forum shopping

introduced by globalization.111

The next four contributions focus on the roles and obligations of institutions,

individual researchers, and involved physicians.

In Institutional Conflicts and
R.e.rponsibilities in an Age ofAcademic-Industry Alliances,11 I focus on the impact of
biotechnology and the genetics revolution on clinical research and the resulting
issue of institutional conflicts of interest. I conclude that the issue of conflicts

of interest transcends, and requires reforms to, the regulatory regimes for both
technology transfer and human subject protections.12

I introduce several

proposals for reform, the foremost being to write uniform, workable, and

enforceable f ederal conflicts of interest standards directly into federal technology
transfer policy.13
Pilar Ossorio and Janet Aeetwood address the roles and responsibilities of

clinical researchers. Ossorio's contribution, entitled Pills, Bills andShills: Physician
R.esearcher's Conflicts of Interest, is a primer on research, emphasizing the multi
faceted nature and, consequentially, the varied roles of, and influences upon,

physician-researchers.14 Ossorio offers suggestions to minimize and manage

conflicts of interest, including the involvement of third parties in the consent

process15 and institutional policies for professional advancement which prioritize
research quality over quantity. 16
Ossorio emphasizes the importance of

disclosure and institutional oversight.17

8.

Erica

Rose, Fina11aa/Conjlkts ojltrltmt: How an"" Managing?,

8 WIDENER L. SYMP. J. 1

(2001).
9. Timothy Caulfield, G�baliz.atio11 ofItrltmls and Cliniwl Rnearch: An Overview ofTrends and
Imm, 8 WIDENER L. SYMP. J. 31 (2001).
10. Stt id
11. Michael J. Malinowski, InstitlllionalConflitis and RupotrnbilititS in an Agt ofAcadmric-lndNstry
Alliatrtts, 8 WIDENER L. SYMP. J. 47 (2001).
12. Su id
13. Stt id at 69-70.
14. Pilar N. Ossorio, Pills, Bills andShi/J.r: Pl!Jsidan-&starchtr's Conflicts ofIntmsl, 8 WIDENER
L. SYMP. J. 75 (2001).
15. Sttid at96-97.
16. Id. at 97.
17. Id at 100.
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In Conflicts of Interest in Clinical &search: Advocating/or Patient-Subjects, Janet

Fleetwood focuses on the doctor-patient relationship and the obligations to

patient-subjects. Fleetwood attributes the ongoing nature of the conflicts of

interest problem t o three major factors: complications to the consent process
attributable to the doctor-patient relationship, lack of sufficient subject-patient
knowledge, and inadequate ongoing oversight by IRBs.18 She concludes that

conflict of interest policies have done little to inform or protect patients.19

The series of symposium articles concludes with a comprehensive treatment

by Patricia Kuszler, entitled Curing Conflicts ofInterest in Clinical &search: Impossible

Dreams and Harsh Realities.20 Kuszler surveys a broad range of conflicts issues,

financial and non-financial, in basic research and the delivery of care as well as
in clinical research. Kuszler concludes tha� "conflicts of interest, both financial

and non-financial are now deeply embedded in the fabric of biomedical
research"21

and,

consequentially,

"the traditional boundaries

and

values

differential between the market and the ivory tower of academia are blurred, if
not completely obliterated."22

In addition to these pieces originating from the conference proceedings, this

issue includes a book review by William Charles Lucas of Cynthia Robbins
Roth's book, FROM ALCHEMY TO !PO: THE BUSINESS OF BIOTECHNOWGY. 2'
In reviewing FROM ALCHEMY TO IPO, 24 a best-selling "industry insider's"
account of the biotechnology sector, Lucas draws heavily from his own

experience as the Vice President and Associate General Counsel of Pharmacia
and former Vice President and General Counsel of Zeneca Pharmaceuticals.

Lucas concludes that "the book ...provide[s] the potential investor with a

helpful compendiwn of due diligence concerns and enough background to begin

to understand this very complex industry."25

Michael J. Malinowski
Faculty Chair

18. Janet Fleetwood, Conflict1 of Inteml in Clinical &mmh: Advocatingfar Politnt-S11ijec/1, 8

WIDENER L. SYMP. J. 105, 105-06 (2001).
19. Seeitl at 106.
20. Patricia C. Kuszler, CmingConjlicuoflntemtin Clinical&mmh: Impouible Drran11 and Harsh
Reolitie1, 8 WIDENER L. SYMP. J. 115 (2001).
21. Id at 152.
22. Id
23. William Charles Lucas, From Alchemy to IPO: The B11sint11 ofBiot1&hnology, 8 WIDENER L.
SYMP. J. 153 (2001) (book review).
24. CYNTHIA ROBBINS-ROTH, FROM ALCHEMY TO IPO (2000).

25. See Lucas, sttpra note 23,

at

155.
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